- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Valneva (VLS)
The Valneva share price today is 2.475, view EPA VLS stock exchange data. Track the latest Valneva share price with real-time updates on VLS stock performance including market cap, day range, 52-week range and dividend yield. Access VLS charts, earnings dates and analyst estimates to support your investment decisions.
Currency in EUR
2.475
+0.002(+0.08%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.460
2.540
52 wk Range
2.135
5.415
VLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.4602.540
52 wk Range
2.1355.415
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VLS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
5.233
Upside
+111.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Valneva receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Valneva receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 13D/A Valneva SE For: 12 May
- Investing.com
- Form 13G VALNEVA SE For: 12 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
6 Buy
0 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.233
(+111.45% Upside)
Earnings
Latest Release
13-05-2026
EPS / Forecast
-0.18 / -0.07
Revenue / Forecast
30.9M / 45.07M
Compare VLS to Peers and Sector
Metrics to compare | VLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | −4.2x | −0.5x | |
PEG Ratio | 0.07 | −0.19 | 0.00 | |
Price/Book | 6.1x | 0.0x | 2.6x | |
Price / LTM Sales | 3.0x | 21.9x | 3.1x | |
Upside (Analyst Target) | 110.1% | 170.3% | 53.0% | |
Fair Value Upside | Unlock | −1.0% | 6.3% | Unlock |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Valneva (VLS) Share Price Today?
The Valneva share price today is 2.475.
What is the current Valneva (VLS) share price and day range?
As of 23-05-2026, the Valneva share price is 2.475, with a previous close of 2.473. The share price has ranged from 2.460 to 2.540 today, while the 52-week range spans from 2.135 to 5.415.
What Is the Valneva Market Cap?
As of today, Valneva market cap is 469.380M.
What Is the Valneva (VLS) Share Price Target?
The average 12-month share price target for Valneva is 5.233, with a high estimate of 7.5 and a low estimate of 2.1. 6 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +111.45% Upside potential.
What Is Valneva's Earnings Per Share (TTM)?
The Valneva EPS (TTM) is -0.792.
When Is the Next Valneva Earnings Date?
Valneva will release its next earnings report on 13-08-2026.
From a Technical Analysis Perspective, Is VLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Valneva Trade On?
Valneva is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Valneva?
The stock symbol for Valneva is "VLS."
How Many Times Has Valneva Stock Split?
Valneva has split 3 times.
How Many Employees Does Valneva Have?
Valneva has 674 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.